Nu Skin Enterprises (NYSE:NUS) issued an update on its first quarter 2020
After-Hours earnings guidance on Wednesday morning. The company provided earnings per share guidance of 0.23-0.33 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $0.74. The company issued revenue guidance of $480-510 million, compared to the consensus revenue estimate of $596.52 million.Nu Skin Enterprises also updated its FY 2020
After-Hours guidance to 2.00-2.40 EPS.
NYSE NUS traded up $0.48 during trading hours on Friday, reaching $30.45. 1,389,299 shares of the company traded hands, compared to its average volume of 642,417. Nu Skin Enterprises has a 12 month low of $29.09 and a 12 month high of $64.90. The company has a current ratio of 2.01, a quick ratio of 1.24 and a debt-to-equity ratio of 0.50. The stock has a market capitalization of $1.96 billion, a PE ratio of 14.71, a PEG ratio of 1.14 and a beta of 0.78. The company has a 50 day moving average of $38.18 and a two-hundred day moving average of $40.32.
Nu Skin Enterprises (NYSE:NUS) last posted its quarterly earnings data on Wednesday, February 12th. The company reported $0.72 EPS for the quarter, meeting the Zacks’ consensus estimate of $0.72. Nu Skin Enterprises had a net margin of 4.59% and a return on equity of 23.52%. The firm had revenue of $583.36 million for the quarter, compared to the consensus estimate of $582.49 million. During the same period in the prior year, the firm posted $1.05 EPS. The firm’s revenue was down 14.6% compared to the same quarter last year. On average, equities research analysts anticipate that Nu Skin Enterprises will post 3.11 earnings per share for the current year.
A number of research analysts have commented on NUS shares. DA Davidson reiterated an in-line rating and set a $35.00 price objective on shares of Nu Skin Enterprises in a research note on Thursday. They noted that the move was a valuation call. Stifel Nicolaus upgraded shares of Nu Skin Enterprises from a sell rating to a hold rating and increased their price objective for the company from $38.50 to $45.00 in a research note on Tuesday, October 29th. Citigroup reduced their price objective on shares of Nu Skin Enterprises from $43.00 to $33.00 and set a neutral rating on the stock in a research note on Friday. Bank of America reduced their price objective on shares of Nu Skin Enterprises from $40.00 to $30.00 and set an underperform rating on the stock in a research note on Thursday. Finally, Zacks Investment Research downgraded shares of Nu Skin Enterprises from a hold rating to a sell rating and set a $44.00 price objective on the stock. in a research note on Monday, November 11th. Two equities research analysts have rated the stock with a sell rating, five have assigned a hold rating and two have issued a buy rating to the stock. Nu Skin Enterprises has a consensus rating of Hold and a consensus target price of $44.63.
Nu Skin Enterprises Company Profile
Nu Skin Enterprises, Inc develops and distributes anti-aging personal care products and nutritional supplements under the Nu Skin and Pharmanex category brands worldwide. It provides skin care systems, including ageLOC Me customized skin care systems, ageLOC Spa systems, and ageLOC LumiSpa skin treatment and cleansing devices; and Epoch products, as well as a range of other cosmetic and personal care products.
Further Reading: Shanghai Stock Exchange Composite Index
Receive News & Ratings for Nu Skin Enterprises Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nu Skin Enterprises and related companies with MarketBeat.com's FREE daily email newsletter.